Home/Filings/4/0001192482-19-000425
4//SEC Filing

Brennan Nora 4

Accession 0001192482-19-000425

CIK 0001561921other

Filed

Nov 12, 7:00 PM ET

Accepted

Nov 13, 8:52 PM ET

Size

7.2 KB

Accession

0001192482-19-000425

Insider Transaction Report

Form 4
Period: 2019-11-13
Brennan Nora
Chief Financial Officer
Transactions
  • Conversion

    Common Stock

    2019-11-13+3,4913,668 total
  • Conversion

    Series B Preferred Stock

    2019-11-1386,2000 total
    Common Stock (3,491 underlying)
Footnotes (3)
  • [F1]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
  • [F2]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
  • [F3]Reflects 177 shares of common stock received by the reporting person as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

Issuer

TELA Bio, Inc.

CIK 0001561921

Entity typeother

Related Parties

1
  • filerCIK 0001790215

Filing Metadata

Form type
4
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 8:52 PM ET
Size
7.2 KB